The revolutionary BiVACOR heart device was moved to Phase 2 of FDA trials after success in five human patients.

The global clinical trials market was valued at USD 60.56 billion in 2024 and is predicted to surge USD 92.12 billion by 2033 with a registered CAGR of 4.84% during the forecast period 2024 to 2033.

Ex-Takeda VP Tauhid Ali, Ph.D., with broad leadership and drug development experience becomes Board DirectorSeasoned regulatory strategist Darren Rubin becomes VP, Amalive, heading development of the ...

In the past week, a Boston biotech led by longtime industry CEO Harvey Berger said it plans to shut down, while another ...

Historically, clinical trials have under-represented women and minorities. Clinical Trial Media's Cara Brant offers ...

Flourish Research, a multi-site clinical trial organization focused primarily on cardiovascular, metabolic, neuroscience, and ...

NaviFUS is Taiwan's first and only high-end medical device company leveraging advanced chip integration and chip deployment, cementing its leadership in the global market. As the demand for ...

An official who oversees a team at the Food and Drug Administration that reviews Neuralink Corp. devices was fired, according to an email the agency sent to staff Tuesday morning viewed by Bloomberg.

From my colleague Adam Feuerstein: Biogen and Stoke Therapeutics have signed a partnership agreement to co-develop and sell ...

NaviFUS Corp. is revolutionizing brain disorder treatments through ultrasound-based solutions, leveraging Taiwan's advanced chip technology. By integrating ICT capabilities into high-end medical ...

(NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare ...